Delving into the Latest Updates on Flurbiprofen with Synapse

Characterization of Relative Bioavailability of a Newly Developed Esflurbiprofen Topical System (EFTS) in Comparison with a Marketed Oral Flurbiprofen-containing Tablet Formulation After Multiple-dose Administration Including EFTS Adhesion Assessment - a Phase I, Open-label, Randomized, 2-period, Cross-over Study in Healthy Subjects

This study is a single-center, open-label, multiple-dose trial performed in a 2-period, 2- sequence-cross-over design in healthy volunteers. The primary purpose of this study is to assess non-superiority of the bioavailability of TK-254RX compared with that of a marketed oral flurbiprofen-containing tablet formulation in healthy volunteers in a 2-period, 2- sequence-cross-over design and evaluate adhesion of TK-254RX. Secondary purpose is to assess safety of TK-254RX and residual amount of the patch.

Start Date21 Jan 2025

Sponsor / Collaborator

Teikoku Seiyaku Co. Ltd.

[+3]

ChiCTR2500095858

/ SuspendedNot ApplicableIIT

Clinical Analysis of Oxelidine Combined with Flurbiprofen and Dexmedetomidine for Postoperative Intraumatic Pump in Orthopedic Patients

Start Date15 Jan 2025

Sponsor / Collaborator-

ChiCTR2400093113

/ SuspendedPhase 4IIT

Safety of remazolam combined with flurbiprofen ester in painless X-ray hysterosalpingography

Start Date01 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with Flurbiprofen

Login to view more data

100 Translational Medicine associated with Flurbiprofen

Login to view more data

100 Patents (Medical) associated with Flurbiprofen

Login to view more data

5,628

Literatures (Medical) associated with Flurbiprofen

01 Apr 2025·Journal of Molecular Structure

Design, synthesis, and computational docking techniques of novel 1,2,3‒triazole‒tetrazole hybrids as potential leads in the development of anticancer agents

Author: Allaka, Tejeswara Rao ; Vudari, Balaraju ; Vellaiyan, Venkatesan ; Nagarajaiah, Honnappa ; Chepuri, Kalyani ; Bhoomandla, Srinu

New flurbiprofen linked 1,2,3-triazole and tetrazole scaffolds have been designed and synthesized using a Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC).All the synthesized compounds were examined for the growth inhibition of HepG2, HuH7, MCF-7, and T-47D tumor cells and binding with focusing on the human cytochrome P 450 2C9 active site was investigated using mol. modeling.There was a strong correlation between the data from the docking studies and the biol. screening results.The cell lines that responded to the novel compound′s effects the best were HepG2 and MCF-7.Compound 5j was the most efficacious derivative among the four cancer cells (HepG2, HuH7, MCF-7, and T-47D) having IC₅₀ values of 1.89 ± 0.103, 2.86 ± 0.167, 1.66 ± 0.056, and 3.55 ± 0.045 μM, resp. and it had greater activity than doxorubicin.In addition, an in silico docking anal. was carried out to confirm the results of the experimentThe results highlight the potential of our triazole-bridged tetrazoles when combined with flurbiprofen (PDB: 1R9O) to enter the active site of human cytochrome P 450 2C9.The proposed binding mode of ligand 5 g was shown three hydrogen bonding via tetrazole with Glu427 (N24...OE1), triazole with Ala280 (N17...O) and fluoro group with Arg80 (F28...NH2) residues their internuclear distances are 2.89 Å, 2.71 Å, and 3.19 Å resp.Furthermore, the ADMET profile was assessed for each mol., and the findings of the in vitro and in silico investigations indicate that the triazoles incorporating tetrazole provide important new information for the creation of innovative anti-cancer treatments.

01 Apr 2025·Separation and Purification Technology

Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography

Author: Nováková, Lucie ; Plachka, Katerina ; Svec, Frantisek ; Plachká, Kateřina ; Pilařová, Veronika ; Gazarkova, Tatana ; Novakova, Lucie ; Švec, František ; Gazárková, Taťána ; Pilarova, Veronika ; Garrigues, Jean-Christophe

The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH₃, and methanol + 2% H₂O, in CO₂.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.

01 Mar 2025·Environmental Toxicology and Chemistry

The determination of wide-range pharmaceuticals class in Erzurum biological wastewater treatment plant using liquid chromatography coupled to tandem mass spectrometry: occurrence, treatment efficiency, and environmental risk assessment

Article

Author: Eren, Zeynep

AbstractPharmaceuticals as an important group of contaminants of emerging concern (CECs) are unintentionally discharged into the aquatic environment due to lack of advanced treatment of classical wastewater treatment plants (WWTPs). Therefore, the detection and monitoring studies of pharmaceuticals and personal care products (PPCPs) in an aquatic environment are getting more important as well as the definition of their ecological risks to the aquatic ecosystem. To conduct these studies successfully, it is necessary to develop sensitive, robust, selective, and reliable methods to be able to analyze PPCPs. This study was carried out in the biological WWTP (BWWTP) of Erzurum City, Türkiye, to investigate the treatment efficiency of pharmaceuticals in the plant and to assess the ecological risks for the Karasu River where treated wastewater is discharged into it. For this purpose, a wide range of pharmaceutical classes in influent wastewater (IWW) and effluent wastewater samples taken from Erzurum BBWWTP, Türkiye was simultaneously identified and quantified with liquid chromatography coupled with tandem mass spectrometry following liquid phase extraction for sample preparation. A total of 55 active pharmaceutical groups in 25 general drug groups (29 subgroups) were detected, with the highest average ratios being 82.459%, 7.306%, 4.949%, and 2.145% for analgesic-anti-inflammatory, antiepileptic, diabetic, and antipyretic pharmaceuticals groups, respectively, in IWW. Although flurbiprofen from the analgesic-anti-inflammatory pharmaceuticals group was treated with the average efficiency of 66.13% during the 12-month treatment period, it had a high risk quotient due to the very high initial concentration in WWT in the range of 809.01–22,901.10 µg/L.

1

News (Medical) associated with Flurbiprofen

17 Apr 2023

·www.drugs.com

Get Pain Relief With the Most Common Arthritis Medications

MONDAY, April 17, 2023 -- Arthritis is a common disease that causes pain and inflammation in different body joints, making it difficult to enjoy everyday tasks and physical activity. Fortunately, there are many different medications for arthritis. Depending on what type of arthritis you have and its severity, an arthritis medication may help you manage pain and other symptoms. Here is a breakdown of the most common arthritis medications, how they work and their potential side effects. The Arthritis Foundation lists the following as the medications used to treat arthritis: Analgesics including acetaminophen (Tylenol) and opioids Nonsteroidal anti-inflammatory drugs (NSAIDs) Corticosteroids Disease-modifying antirheumatic drugs (DMARDs) including biologics and targeted DMARDs Analgesics The Arthritis Foundation reports that analgesics may help with mild to moderate pain, but they will not help with the inflammation associated with arthritis. Analgesics work in the nervous system and alter how your brain perceives pain. They can be used to treat the pain associated with any type of arthritis, although more effective options are available. Analgesics can be opioid, non-opioid or a combination. Common analgesics are: Acetaminophen (Tylenol) Codeine Oxycodone Fentanyl Hydrocodone Potential side effects: Kidney damage Liver damage Addiction Constipation Gastrointestinal bleeding Use caution when taking these medications; take only as prescribed. NSAIDs NSAIDs work by blocking prostaglandin. According to the Cleveland Clinic , one role prostaglandins play is forming clots and causing inflammation at the site of an injury. NSAIDs are used to treat the pain and inflammation associated with rheumatoid arthritis and osteoarthritis . Common over-the-counter (OTC) NSAIDs are: Aspirin (Bayer, St. Joseph, Anacin, Excedrin and more) Ibuprofen (Motrin, Advil) Naproxen sodium (Aleve) Prescription NSAIDs are: Celecoxib (Celebrex) Diclofenac (Voltaren, available by brand name in topical form) Fenoprofen (Nalfon) Indomethacin (Indocin, available by brand name in liquid form) Ketorolac tromethamine (Toradol) Meclofenamate sodium (Meclomen) Diflunisal (Dolobid) Tolmetin (Tolectin) Ketoprofen (Orudis) Flurbiprofen (Ansaid) Potential side effects of NSAIDs are: Increased risk of stomach and bowel issues like ulcers and bleeding Increased risk of stroke Heart problems Stomach pain Nausea Diarrhea/constipation Corticosteroids According to the Arthritis Foundation , corticosteroids mimic cortisol, a hormone your body produces naturally. They are used to treat inflammatory types of arthritis, including rheumatoid arthritis and psoriatic arthritis. They are great for short-term relief of inflammation but are not recommended for long-term use because of their side effects. Your doctor may prescribe a lower dose if you require them for long-term use. Common corticosteroids: Prednisone (Deltasone, Prednicot, Cotolone) Prednisolone (Orapred, Omnipred) Cortisone (Cortone) Hydrocortisone (Cortef, Hydrocort) Triamcinolone (Aristocort) Dexamethasone (Decadron) Common side effects of corticosteroids: Blood sugar spikes Weight gain Bone loss Risk of cataracts High blood pressure Infections Mood changes DMARDs The Arthritis Foundation says that DMARDs work with the body to “stop or slow the disease process in inflammatory forms of arthritis.” They work by blocking inflammation. There are many different DMARDs on the market, and they all have different ways of working in the body. Conventional DMARDs work by broadly suppressing the immune system. Often they are used in combination with other therapies. Targeted DMARDs block specific pathways inside immune cells. Biologic DMARDs are produced by live cells and work on specific immune proteins called cytokines. Common DMARDs: Apremilast (Otezla) Baricitinib (Olumiant) Cyclophosphamide (Cytoxan) Cyclosporine (Gengraf, Neoral) Hydroxychloroquine (Plaquenil) Leflunomide (Arava) Methotrexate (Otrexup, Rasuvo, RediTrex) Mycophenolate mofetil (CellCept) Sulfasalazine (Azulfidine) Tofacitinib (Xeljanz, Xeljanz XR) According to the Cleveland Clinic , common side effects of traditional DMARDs include: Loss of appetite Nausea Diarrhea Abdominal pain Rash, allergic reaction Liver problem Increased risk of infection Low blood cell counts Common side effects of biologic DMARDs include: Increased risk of common and serious infections Reactivation of tuberculosis, herpes zoster, and hepatitis B and C Increased cholesterol levels, increased liver enzymes and low blood cell counts Increased risk of clotting When prescribed DMARDs, inform your doctor of any other medications, including over-the-counter medicines, you are taking to avoid drug interactions. Some of these medications can cause teratogenicity (defects in a developing fetus.) Writing recently in the Journal of the American Academy of Physician Assistants (JAAPA ), physician assistant Michelle DiBiase and Dr. Samantha Kohn remind people that "The mainstay of pharmacologic therapy is early intervention with use of nonbiologic and biologic DMARDs together with adjunctive medications such as NSAIDs, oral and intra-articular corticosteroids, and analgesic medications, including opioids." Your primary care provider or rheumatologist will work closely with you to determine which medications are best for your treatment. It is vital to keep them apprised of any side effects and let them know if the treatment is ineffective. They can work with you to find a treatment that helps relieve the pain and inflammation caused by arthritis. Posted April 2023

Drug Approval

100 Deals associated with Flurbiprofen

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00330	Flurbiprofen	M01AE09 M02AA19 R02AX01 S01BC04	DB00712

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Myalgia	Japan	Mikasa Seiyaku Co. Ltd.	14 Mar 2008
Periarthritis	Japan	Mikasa Seiyaku Co. Ltd.	14 Mar 2008
Pharyngitis	Australia	Reckitt Benckiser (Australia) Pty Ltd.	01 Dec 2007
Analgesia	Japan	Tokuhon Corp.	14 Mar 2001
Inflammation	Japan	Tokuhon Corp.	14 Mar 2001
Musculoskeletal Pain	Japan	Taikyo Pharmaceutical Co. Ltd.	10 Mar 1992
Bursitis	Japan	Kaken Pharmaceutical Co., Ltd.	01 Sep 1989
Epicondylitis	Japan	Kaken Pharmaceutical Co., Ltd.	01 Sep 1989
Pain	Japan	Kaken Pharmaceutical Co., Ltd.	01 Sep 1989
Tenosynovitis	Japan	Kaken Pharmaceutical Co., Ltd.	01 Sep 1989
Tumescence	Japan	Kaken Pharmaceutical Co., Ltd.	01 Sep 1989
Low Back Pain	Japan	Kaken Pharmaceutical Co., Ltd.	31 Oct 1981
Periodontitis	Japan	Kaken Pharmaceutical Co., Ltd.	31 Oct 1981
Pulpitis	Japan	Kaken Pharmaceutical Co., Ltd.	31 Oct 1981
Osteoarthritis	Japan	Kaken Pharmaceutical Co., Ltd.	19 Apr 1979
Rheumatoid Arthritis	Japan	Kaken Pharmaceutical Co., Ltd.	19 Apr 1979

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteoarthritis, Knee	Phase 3	China	Mikasa Seiyaku Co. Ltd.	31 Mar 2020
Osteoarthritis, Knee	Phase 3	China	Beijing Tide Pharmaceutical Co., Ltd.	31 Mar 2020
Moderate pain	Phase 2	China	Wuhan Daan Pharmacy Co. Ltd.	08 Nov 2013
Acute pharyngitis	Phase 2	United States	Reckitt Benckiser LLC	01 Sep 2013
Cough	Phase 1	Australia	Reckitt Benckiser LLC	01 Jul 2023
Respiratory Tract Infections	Phase 1	Australia	Reckitt Benckiser LLC	01 Jul 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04425902 (CTgov)	Phase 1	HIV Infections	20	pravastatin+omeprazole+metoprolol+montelukast+digoxin+midazolam+caffeine+flurbiprofen (Treatment A: Probe Substrates)	bdpradithb(fymhgpghhi) = eskjtiwiuq dicokebifq (uhgsrvnycz, oxispuppte - egrxyusfxw) View more	-	23 May 2022
				GSK3640254 (Treatment C: Probe Substrates + GSK3640254 200 mg)	bdpradithb(fymhgpghhi) = dgexeycube dicokebifq (uhgsrvnycz, vsgwlikbbt - zcxnphjkai) View more
NCT01048866 (CTgov)	Phase 3	Pharyngitis	198	acetaminophen 650mg+flurbiprofen (Flurbiprofen 8.75 mg Lozenge)	gczyfokjou(pjlregivpm) = cyexujnumw ujrrtmfbaz (hbhffyudae, jdkmgwyaci - omqzmgrbbg) View more	-	21 Sep 2017
				placebo+acetaminophen 650mg (Placebo Lozenge)	gczyfokjou(pjlregivpm) = ikkwvqkfro ujrrtmfbaz (hbhffyudae, hrcqmxfobn - wdhrecxgoy) View more
NCT01049334 (CTgov)	Phase 3	Pharyngitis	204	Flurbiprofen (Flurbiprofen 8.75 mg Lozenge)	fgfukswbjy(cbidsnfcni) = uuyxeyfcmu pxyfmvnsfx (fuaqtrnrip, mugcnwhtbz - ksapzuouun) View more	-	21 Sep 2017
				Placebo (Placebo Lozenge)	fgfukswbjy(cbidsnfcni) = wnceynncse pxyfmvnsfx (fuaqtrnrip, yqfyajbwws - qjmbslfymm) View more
NCT01986361 (CTgov)	Phase 3	Acute pharyngitis	122	flurbiprofen (Flurbiprofen 8.75 mg Lozenge)	kdmvsoqjjl(xbrslxbayh) = xhsgrwjmsq zyjhefnmme (zaumibxdon, otucetkplf - cbooaebmno) View more	-	24 Aug 2017
				placebo (Placebo Lozenge)	kdmvsoqjjl(xbrslxbayh) = yxgkoepgvp zyjhefnmme (zaumibxdon, cqymjbexfq - qtndzbcyjz) View more
ARVO2017	Not Applicable	Macular Edema	20	Nepafenac	(zroamvcthe) = unrjzaxjxe akggozgthc (pjikmplwld )	-	07 May 2017
				Diclofenac	(zroamvcthe) = sejeizcgxa akggozgthc (pjikmplwld )
NCT01048866 \| NCT01049334 (Pubmed \| Int J Clin Pract)	Phase 3	Streptococcal Infections	402	Flurbiprofen 8.75 mg lozenges	bldjdrcviz(ruzefogyke) = A single flurbiprofen lozenge provided significantly greater relief than placebo for all three throat symptoms, lasting 3-4 h for patients with and without Strep A/C itmxxoctnb (muezlekhuh ) View more	Positive	01 Jan 2015
Iritis prevention study (ARVO2004)	Not Applicable	Iritis	64	Topical flurbiprofen 300 mcg/ml	(ivyzbpoxuh) = 7/30 treated patients and 0/34 control patients had increased stinging rxbcqjmcxa (odvdzkouqb )	Negative	01 May 2004
				Placebo